Program
nirogacestat
Also written as “PF-03084014”, “Nirogacestat” and “Nirogacestat oral tablet”.
Its studies are mostly in Multiple Myeloma · Desmoid Tumors · Ovarian Neoplasms · Leukemia · Breast Neoplasms, led by 4 companies.
Drug pageNirogacestat: every studyAll 24 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck KGaA, Darmstadt, Germany | 62 open or running | phase 4since Jul 31, 2025 | Dec 17, 2018 | May 28, 2027phase 2 · NCT07170644 |
| Pfizer | 60 open or running | phase 2since Apr 2, 2014 | Apr 6, 2009 | none ahead |
| GlaxoSmithKline | 33 open or running | phase 2since Jul 22, 2025 | Jul 22, 2025 | none ahead |
| Precision BioSciences | 10 open or running | phase 1since Nov 12, 2019 | Nov 12, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 1 study since Apr 6, 2009.
- Jun 10, 2013Phase 1 study in Breast Cancer MetastaticPfizer · NCT01876251 · 30 enrolled · United States, Belgium, Italy and more
- Apr 2, 2014Phase 2 study in Pancreatic NeoplasmsPfizer · NCT02109445 · 3 enrolled · United States
- Nov 20, 2014Phase 2 study in Triple Negative Breast NeoplasmsPfizer · NCT02299635 · 19 enrolled · United States, Hungary, Italy and more
- Jun 2, 2015Phase 1 study in Advanced Solid TumorsPfizer · NCT02462707
- Jun 9, 2016Named nirogacestatINNProposed as its International Nonproprietary Name in WHO's List 115 · before, PF-03084014
- Dec 17, 2018Merck KGaA, Darmstadt, Germany’s first study: phase 3 study in Desmoid TumorsNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT03785964 · 142 enrolled · United States, Belgium, Canada and more
- Nov 12, 2019Precision BioSciences’ first study: phase 1 study in Multiple MyelomaNew to Precision BioSciencesPrecision BioSciences · NCT04171843 · 48 enrolled · United States
- Oct 8, 2021Phase 2 study in Multiple MyelomaPfizer · NCT05090566 · 46 enrolled · United States, Canada
- Apr 13, 2022Phase 2 study in Granulosa cell tumor of the ovaryMerck KGaA, Darmstadt, Germany · NCT05348356 · 53 enrolled · United States, Canada, Poland
- Jul 22, 2025GlaxoSmithKline’s first study: phase 2 study in Multiple MyelomaNew to GlaxoSmithKlineGlaxoSmithKline · NCT07084896 · 106 enrolled · United States, Australia, Canada and more
- Jul 31, 2025Phase 4 study in Desmoid TumorsMerck KGaA, Darmstadt, Germany · NCT07176689 · 50 planned · Belgium, Germany, Italy and more
- Jul 31, 2025Phase 2 study in Desmoid TumorsMerck KGaA, Darmstadt, Germany · NCT07170644 · 20 enrolled · Japan
- Aug 7, 2025Phase 1 study in HealthyMerck KGaA, Darmstadt, Germany · NCT07171619 · 24 enrolled · United States
- Aug 25, 20252 phase 2 studies in Multiple MyelomaGlaxoSmithKline · NCT07150104, NCT07150091
- Nov 19, 2025Phase 1 study in HealthyMerck KGaA, Darmstadt, Germany · NCT07259330 · 20 enrolled · Netherlands
Ahead
- May 28, 2027Primary completion: phase 2 study in Desmoid TumorsMerck KGaA, Darmstadt, Germany · NCT07170644
- Feb 26, 2031Primary completion: phase 4 study in Desmoid TumorsMerck KGaA, Darmstadt, Germany · NCT07176689
TargetBeta
“Gamma-secretase inhibitor; Gamma-secretase inhibitor”ChEMBL 37, by rule
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07259330Healthy · Netherlands | 1 | Completed | Merck KGaA, Darmstadt, Germany | Mar 27, 2026 | 20 |
| NCT07150104Multiple Myeloma · Brazil, Canada, France and more | 2 | Active, not recruiting | GlaxoSmithKline | Apr 17, 2025 | 14 |
| NCT07150091Multiple Myeloma · United States, Brazil, Canada and more | 2 | Active, not recruiting | GlaxoSmithKline | Apr 17, 2025 | 20 |
| NCT07171619Healthy · United States | 1 | Completed | Merck KGaA, Darmstadt, Germany | Nov 10, 2025 | 24 |
| NCT07176689Desmoid Tumors · Belgium, Germany, Italy and more | 4 | Recruiting | Merck KGaA, Darmstadt, Germany | Feb 26, 2031 | 50 |
| NCT07170644Desmoid Tumors · Japan | 2 | Active, not recruiting | Merck KGaA, Darmstadt, Germany | May 28, 2027 | 20 |
| NCT07084896Multiple Myeloma · United States, Australia, Canada and more | 2 | Active, not recruiting | GlaxoSmithKline | Apr 17, 2025 | 106 |
| NCT05348356Granulosa cell tumor of the ovary · United States, Canada, Poland | 2 | Completed | Merck KGaA, Darmstadt, Germany | Jul 8, 2025 | 53 |
| NCT05090566Multiple Myeloma · United States, Canada | 2 | Terminated | Pfizer | Feb 13, 2025 | 46 |
| NCT04171843Multiple Myeloma · United States | 1 | Terminated | Precision BioSciences | Oct 19, 2022 | 48 |
| NCT03785964Desmoid Tumors · United States, Belgium, Canada and more | 3 | Completed | Merck KGaA, Darmstadt, Germany | Apr 7, 2022 | 142 |
| NCT02462707Advanced Solid Tumors | 1 | Withdrawn | Pfizer | Jun 2016 | 0 |
| NCT02299635Triple Negative Breast Neoplasms · United States, Hungary, Italy and more | 2 | Terminated | Pfizer | Jan 14, 2016 | 19 |
| NCT02109445Pancreatic Neoplasms · United States | 2 | Terminated | Pfizer | Nov 6, 2014 | 3 |
| NCT01876251Breast Cancer Metastatic · United States, Belgium, Italy and more | 1 | Terminated | Pfizer | Dec 24, 2015 | 30 |
| NCT00878189Neoplasms by Histologic Type · United States, Italy | 1 | Completed | Pfizer | Jan 10, 2013 | 72 |
How it is read
Names in the registry
- “PF-03084014”, 10 entries
- “Nirogacestat”, 7 entries
- “Nirogacestat oral tablet”, 2 entries
- “Nirogacestat and Famotidine”, 1 entry
- “Nirogacestat and Rabeprazole”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 5 studies
- Desmoid Tumors, 3 studies
- Ovarian Neoplasms, 1 study
- Leukemia, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.